SKIN CARE C- (UNTREATED CELLS) C+ (100µM METFORMIN CLARIVINE 0.65% CLARIVINE 2.5%
71
+6.40%
+32.99%
+53.44% ■ Hoechst ■ LC3B
+9.78% Figure 2: Autophagic activity measured by LC3 immunodetection in HDF
cellular recycling, reducing senescence markers like SA-β-galactosidase (Figure 3). A marked reduction of intracellular ageing
pigments lipofuscin (34%) in fibroblasts and melanin content (29%) was demonstrated in senescent melanocyte models.
Clinical evaluation (in vivo assays) To confirm the biological findings in human subjects, grapevine secretome underwent clinical validation through three randomized, double-blind, placebo-controlled studies in multi-ethnic panels composed of both Caucasian and Asian volunteers with signs of photoageing, uneven pigmentation, dehydration, and fine lines. In in vivo 1 and in vivo 2, a formulation
containing grapevine secretome was applied twice daily over 28 to 56 days. Key endpoints were assessed to proof the fasting-mimicking and glass skin effect as well as well-ageing benefits in short term demonstrated in in vivo 3.
In vivo 1: The fasting-mimicking effect (Caucasian panel) Clinical studies demonstrate that grapevine secretome delivers visible and measurable improvements similar to those observed in fasting in Caucasian volunteer panel (Figure 5 and 6) demonstrating grapevine secretome’s dual action: visible aesthetic benefits and deeper cellular renewal. By reducing oxidative stress and skin surface
roughness (Figure 4) and promoting cellular recycling mechanisms, grapevine secretome enhances long-term skin resilience and vitality. This contributes to a more even tone, healthier appearance, and improved radiance. Furthermore, a significant reduction in the skin melanin index was observed—27% at day 28 and 28.9% at day 56, demonstrating its
www.personalcaremagazine.com
Figure 3: Optical microscopy images reveal that grapevine secretome significantly decreases SA-β- galactosidase activity—a key marker of cellular senescence—compared to the untreated control
effective depigmenting action and contribution to a more uniform complexion (Figure 5).
In vivo 2: Radiance, pigmentation and texture improvement (Asian panel) The clinical evaluation of grapevine secretome in the Asian panel demonstrates significant improvements across key markers of skin quality. The active ingredient notably enhanced skin radiance, with increases up to 70.5% at 28 days and up to 96.5% at 56 days, indicating a strong brightening effect. In parallel, skin melanin content was
reduced down to 14.4% at day 28 and 23% by day 56, reflecting a measurable depigmenting
action. Furthermore, skin roughness decreased down to 29.5% at day 28, and maintained a reduction of 33.9% at day 56, supporting its role in improving skin texture and surface smoothness. Collectively, these results confirm grapevine
secretome’s efficacy in promoting a more luminous, even-toned, and refined skin appearance over time.
In vivo 3: Well-ageing benefits in the short term (Caucasian panel) Grapevine secretome showed visible results within 14 days in terms of moisturization and anti-ageing effects. Skin hydration increased significantly, up to 48.1% at day 14 and up to
September 2025 PERSONAL CARE
+43.70%
+138.02%
T56
T28
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
